Nimotuzumab plus gemcitabine prolongs survival in KRAS wild-type pancreatic cancer

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to randomized phase 3 study results presented at ASCO Annual Meeting.Researchers observed the greatest survival benefit among those who had not been treated for biliary obstruction. Nimotuzumab also appeared safe.“These results implied that the addition of nimotuzumab to current treatment regimen will provide benefit and great value to [patients with pancreatic cancer],” Shukui Qin, MD, PhD, of the departmentRead More

Related Articles